Treatment bevacizumab which is also known as Avastin is believed not to be effective in treating nonsmall cell lung cancer (NSCLC) in its advanced stage. It has further been reported that patients above the age of 65 are not at all benefited by the treatment as it doesn’t help in improving the life expectancy.
As scientific evidence to prove the effectiveness of bevacizumab is lacking, the medical practitioners have recommended that patients in the advanced stage of NSCLC should not be prescribed with the therapy.
For long, it was believed that the Avastin is capable of improving the quality of life. However, it is for the very first time when doubts over the effectiveness of the drug have been raised. Although it has been recommended that patients with advanced stage of NSCLC should not prescribed with Avastin, patients with ovarian and colon cancer are still being prescribed with the treatment.
It is hoped that the findings would help in finding effective treatment for advanced stage of cancer. The drug Avastin is quite costlier and therefore, it is advisable that patients should not waste their money over a treatment which doesn’t have any scientific evidence to prove the effectiveness of the drug or treatment.
Good News USA
- Vodafone NZ’s new ‘Red Home’ packages will offer UFB and 150 TV channels
- Vodafone NZ’s full-year profit plunged by more than two-thirds to $56 million
- Vodafone adding 34 European countries to ‘AU$5 per day’ international roaming option
- Telstra launches its new ‘Every Day Connect Data Share Packages’
- Voyager signs “multimillion-dollar deal” with submarine cable group Hawaiki